Oura Ring Gen 4 sensor data, not clinical measurementsN=1 case study, not validated for clinical decisionsHEV diagnosed Mar 18; Day 109 post-ruxolitinibMore
Consumer wearable data can support exploratory review only. The HEV diagnosis, temporally confounded with treatment start, remains a material confounder.

Advanced Sleep Architecture Analysis

167 nights analyzed | 2026-01-08 to 2026-07-02 | Ruxolitinib start: 2026-03-16
Generated 2026-07-02 19:36 · Post-HSCT Patient · Data Jan 08, 2026 to Jul 02, 2026 · Day 109 post-treatment
Fragmentation
1.3trans/hr
0.0% above clinical threshold
Sleep Efficiency
Low
80.7%
78.4% of nights below 85%
Sleep Cycles
5.1/night
21.6% below 4 cycles
REM Latency
80.1min
13.9% above 120 min
HRV Coupling
Abnormal
Abnormal
Abnormal autonomic regulation
Ultradian Period
99.4min
Expected ~90 min (164 nights)
Clinical Interpretation
  • ABNORMAL: HRV is NOT higher during deep sleep than during light sleep. Normal parasympathetic dominance during deep sleep is absent - suggests autonomic dysfunction.
DASHBOARD

Sleep Architecture Analysis (9 panels)

Data window: January 08 to July 02, 2026 · Post-treatment: day 109 on ruxolitinib · Generated: 2026-07-02 19:36
Oura Ring Gen 4 consumer wearable data; N=1 exploratory case study; not a medical device. MIT License · © 2026 The Educational Equality Institute · Oura® is a registered trademark of Oura Health Oy.